Aktis Oncology (AKTS) Stock Price, News & Analysis

Company Overview

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company's activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones. Aktis engages in translational research to move promising molecules from discovery into human testing, and may pursue collaborations or other corporate-development strategies common in the biopharmaceutical sector to accelerate program advancement and broaden development capabilities.

As a publicly traded company on the Nasdaq, Aktis Oncology operates within the broader biotech and pharmaceutical ecosystem and reports progress on its programs to investors and other stakeholders. Public disclosures and regulatory filings are the primary sources for up-to-date information on the company’s pipeline, development timelines and corporate plans. I couldn't find sufficiently detailed, independently verifiable public information on specific products, leadership or geographic headquarters to include here without risking inaccuracy.

Key Stats

• Today's Range: $18.75 to $19.92
• 50-Day Range: $15.19 to $22.08
• 52-Week Range: $14.72 to $29.16
• Volume: 151,400 shs
• Average Volume: 340,151 shs
• Market Capitalization: $1.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $32.00
• Consensus Rating: Buy

Aktis Oncology Stock Analysis - MarketRank™

Aktis Oncology scored higher than 36% of companies evaluated by MarketBeat, and ranked 27th out of 58 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

Aktis Oncology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Aktis Oncology has a consensus price target of $32.00, representing about 68.2% upside from its current price of $19.02.

Amount of Analyst Coverage

Aktis Oncology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Aktis Oncology are expected to decrease in the coming year, from ($1.44) to ($1.88) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for AKTS.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aktis Oncology does not currently pay a dividend.

Dividend Growth

Aktis Oncology does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.17

News Sentiment

Aktis Oncology has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Aktis Oncology this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for AKTS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Aktis Oncology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aktis Oncology insiders have not sold or bought any company stock.

Percentage Held by Institutions

28.84% of the stock of Aktis Oncology is held by institutions.

AKTS Stock Analysis - Frequently Asked Questions

How have AKTS shares performed this year?

Aktis Oncology's stock was trading at $21.75 at the beginning of 2026. Since then, AKTS stock has decreased by 12.6% and is now trading at $19.02.

How were Aktis Oncology's earnings last quarter?

Aktis Oncology (NASDAQ:AKTS) released its quarterly earnings results on Monday, March, 30th. The technology company reported ($18.17) earnings per share for the quarter. The technology company earned $1.87 million during the quarter.

When did Aktis Oncology IPO?

Aktis Oncology (AKTS) raised $300 million in an initial public offering on Friday, January 9th 2026. The company issued 17,650,000 shares at $16.00-$18.00 per share.

When does Aktis Oncology's lock-up period expire?

Aktis Oncology's lock-up period expires on Wednesday, July 8th. Aktis Oncology had issued 17,650,000 shares in its public offering on January 9th. The total size of the offering was $317,700,000 based on an initial share price of $18.00. After the end of Aktis Oncology's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Aktis Oncology?

Shares of AKTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aktis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aktis Oncology investors own include Enovix (ENVX), Luminar Technologies (LAZR), Ginkgo Bioworks (DNA), NVIDIA (NVDA), Rambus (RMBS), Globant (GLOB) and Compass Pathways (CMPS).

Company Calendar

• Last Earnings: 3/30/2026
• Today: 5/05/2026
• Study update: 5/05/2026
• Next Earnings (Estimated): 5/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:AKTS
• CIK: 2035832
• Web: N/A
• Phone: (978) 237-4380
• Fax: N/A
• Employees: 76
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Aktis Oncology: $32.00
• High Price Target: $34.00
• Low Price Target: $30.00
• Potential Upside/Downside: +64.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $6.50 million
• Price / Sales: 159.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,400,000
• Free Float: N/A
• Market Cap: $1.04 billion
• Optionable: Optionable
• Beta: N/A